Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.683003
Keywords
acute kidney injury; mesenchymal stem cell; immunomodulation; cell therapy; kidney repair; drug-induced AKI; ischemia-reperfusion
Categories
Funding
- National Natural Science Foundation of China [61971441]
- National Key R&D Program of China [2016YFC1305500, 2018YFA0108803]
Ask authors/readers for more resources
Drug-induced nephrotoxicity is a significant cause of acute kidney injury, and recent studies suggest that mesenchymal stem cells may have therapeutic potential in treating this condition. The source of MSCs can impact their immunomodulatory abilities and should be considered in treatment strategies.
Drug-induced nephrotoxicity is an important and increasing cause of acute kidney injury (AKI), which accounts for approximately 20% of hospitalized patients. Previous reviews studies on immunity and AKI focused mainly on ischemia-reperfusion (IR), whereas no systematic review addressing drug-induced AKI and its related immune mechanisms is available. Recent studies have provided a deeper understanding on the mechanisms of drug-induced AKI, among which acute tubular interstitial injury induced by the breakdown of innate immunity was reported to play an important role. Emerging research on mesenchymal stem cell (MSC) therapy has revealed its potential as treatment for drug-induced AKI. MSCs can inhibit kidney damage by regulating the innate immune balance, promoting kidney repair, and preventing kidney fibrosis. However, it is important to note that there are various sources of MSCs, which impacts on the immunomodulatory ability of the cells. This review aims to address the immune pathogenesis of drug-induced AKI versus that of IR-induced AKI, and to explore the immunomodulatory effects and therapeutic potential of MSCs for drug-induced AKI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available